Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effectiveness of lanadelumab in patients with hereditary angioedema with normal C1 inhibitor and FXII mutation.

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology - 1 Sept 2021

Bouillet Laurence, Bocquet Alexis, Belbezier Aude, Boccon-Gibod Isabelle

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Angioedemas, Hereditary
Share to Antibodies, Monoclonal, Humanized
Share to Complement C1 Inhibitor Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Factor XII

Share to Mutation

Share to Treatment Outcome

Source

Identifiers

PMID: 34082125
DOI: 10.1016/j.anai.2021.05.028

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effectiveness of lanadelumab in patients with hereditary angioedema with normal C1 inhibitor and FXII mutation.PMID 34082125Read ↗

Successful use of lanadelumab in an elderly patient with type II hereditary angioedemaSemantic proximity Read ↗

Initial Experience of Long-Term Prophylaxis with Lanadelumab for Hereditary Angioedema in China: a Clinical Observation of Four patients.Semantic proximity Read ↗

A single-centre retrospective study on the clinical characteristics of patients with hereditary angioedema and the therapeutic effect of lanadelumabSemantic proximity Read ↗

Hereditary angioedema with normal C1 inhibitor: clinical characteristics and treatment response with plasma-derived human C1 inhibitor concentrate (Berinert®) in a French cohort.Semantic proximity Read ↗

Real-World Evidence on the Management of Hereditary Angioedema With Normal C1 Inhibitor.Semantic proximity Read ↗

Garadacimab in hereditary angioedema due to normal C1INH with F12/PLG mutations.Semantic proximity Read ↗

A clinical evaluation of patients with known mutations (plasminogen and factor XII) with a focus on prophylactic treatment.Semantic proximity Read ↗

The future of therapeutic options for hereditary angioedema.Semantic proximity Read ↗

Type II hereditary angioedema with an apparently de novo SERPING1 mutation in China: A case report and family screening.Semantic proximity Read ↗

Hereditary angioedema in children: review and practical perspective for clinical managementSemantic proximity Read ↗

Hereditary and acquired angioedema.Semantic proximity Read ↗

Hereditary Angioedema with Normal C1 Inhibitor: Update on Evaluation and Treatment.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.